ABOS

Acumen Pharmaceuticals, Inc.

• Seeking Alpha·3d ago

  Acumen's Late-2026 Sabirnetug Readout Is A Viable Bet

• TipRanks·05/15 09:49

  Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS)

• TipRanks·05/14 06:00

  Acumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price

• TipRanks·05/13 00:44

  Acumen Pharmaceuticals Bets Big on Alzheimer’s Trials

• Seeking Alpha·05/12 15:31

  Acumen expects ALTITUDE-AD top-line results in late 2026 while targeting a mid-2027 IND for 2 EBD candidates

• Benzinga·05/12 12:50

  Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

• PUBT·05/12 12:08

  Acumen Pharmaceuticals posts corporate presentation on sabirnetug Alzheimer’s drug candidate

• TipRanks·05/12 12:07

  Acumen Updates Q1 Results and Alzheimer’s Pipeline Progress

• Seeking Alpha·05/12 11:14

  Acumen Pharmaceuticals GAAP EPS of -$0.33 beats by $0.03

• Reuters·05/12 11:13

  Acumen Pharmaceuticals Q1 net loss narrows

• Benzinga·05/12 11:11

  Earnings Scheduled For May 12, 2026

• PUBT·05/12 11:07

  Acumen Q1 FY26 net loss narrows to $20.7 million; R&D expenses fall to $16.5 million

• Benzinga·05/12 11:01

  Acumen Pharmaceuticals Q1 EPS $(0.33) Beats $(0.36) Estimate

• Reuters·05/12 11:00

  BRIEF-Acumen Pharmaceuticals, Inc. Q1 Income From Operations USD -21.149 Million

• Reuters·05/12 11:00

  ACUMEN PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS